NCT04859543 (PPROSPERITIT) is a NA clinical trial of FoundationOneHeme in Central Nervous System Neoplasms, sponsored by Masaryk University.

Who is sponsoring NCT04859543?

NCT04859543 is sponsored by Masaryk University.

What drugs are being tested in NCT04859543?

Interventions in NCT04859543: FoundationOneHeme.

What condition does NCT04859543 study?

NCT04859543 studies Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain.

Is NCT04859543 still recruiting?

NCT04859543 is currently status unknown. Last updated 26 April 2021.

Last reviewed 2021-04-26 · How we verify

NCT04859543: PPROSPERITIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pediatric Prospective Personalized Immune and Target Identification Trial

Status unknown NA Last updated 26 April 2021

What this trial tests

NA trial testing FoundationOneHeme in Central Nervous System Neoplasms in 80 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 December 2024

31 December 2024

Quick facts

Lead sponsor	Masaryk University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	1 February 2021
Primary completion	1 December 2024
Estimated completion	31 December 2024
Sites	2 locations across Czechia

Drugs / interventions tested

FoundationOneHeme

Conditions studied

Central Nervous System Neoplasms — all drugs for Central Nervous System Neoplasms →
Pediatric Cancer — all drugs for Pediatric Cancer →
GEN1 Gene Mutation — all drugs for GEN1 Gene Mutation →
Tumor, Brain — all drugs for Tumor, Brain →

Sponsor

Masaryk University

Who can join

Adults 1 to 19, any sex, with Central Nervous System Neoplasms or Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Masaryk University trials

Trials by the same sponsor.

NCT07019727 — ESSKA/ESMA ACL Injury Prevention Program in Czech Sport · NA · recruiting
NCT07085247 — The Role of Cutibacterium Acnes in the Development of Degenerative Lumbar Intervertebral Disc Disease · recruiting
NCT06887179 — Point-of-Care Ultrasound in Chronic Heart Failure · NA · not yet recruiting
NCT06906614 — Psychophysiological Stress Response in Medical Students During Simulation-Based Communication Training -Study Protocol · not yet recruiting
NCT06426030 — Validation of Czech Language Versions of Questionnaires for ALS Patients' Functional Status and Biomarker Long-term Foll · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04859543 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masaryk University
Last refreshed: 26 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04859543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing